Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

The Systemic Profile of Soluble Immune Mediators in Patients with Myelodysplastic Syndromes.

Kittang AO, Sand K, Brenner AK, Rye KP, Bruserud Ø.

Int J Mol Sci. 2016 Jul 5;17(7). pii: E1080. doi: 10.3390/ijms17071080.

2.

The protein kinase C agonist PEP005 increases NF-kappaB expression, induces differentiation and increases constitutive chemokine release by primary acute myeloid leukaemia cells.

Olsnes AM, Ersvaer E, Ryningen A, Paulsen K, Hampson P, Lord JM, Gjertsen BT, Kristoffersen EK, Bruserud Ø.

Br J Haematol. 2009 Jun;145(6):761-74. doi: 10.1111/j.1365-2141.2009.07691.x. Epub 2009 Apr 20.

PMID:
19388934
3.

Subclassification of patients with acute myelogenous leukemia based on chemokine responsiveness and constitutive chemokine release by their leukemic cells.

Bruserud Ø, Ryningen A, Olsnes AM, Stordrange L, Øyan AM, Kalland KH, Gjertsen BT.

Haematologica. 2007 Mar;92(3):332-41.

4.

T lymphocyte chemotactic chemokines in acute myelogenous leukemia (AML): local release by native human AML blasts and systemic levels of CXCL10 (IP-10), CCL5 (RANTES) and CCL17 (TARC).

Olsnes AM, Motorin D, Ryningen A, Zaritskey AY, Bruserud Ø.

Cancer Immunol Immunother. 2006 Jul;55(7):830-40. Epub 2005 Nov 3.

PMID:
16267679

Supplemental Content

Loading ...
Support Center